 UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX, a clinical-stage biotechnology company focused on developing its proprietary GammabodyTM platform of bispecific gamma delta T cell engagers bsTCEs to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the SVB Leerink 11th Annual Global Healthcare Conference 2022. The conference is being conducted in a virtual format and the presentation will take place on Thursday, Feb. 17, 2022 at 8:40 a.m. ET. 